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Abstract
Background: The failure of cytotoxic cancer regimens to cure the most drug-resistant, well-differentiated solid tumors has
been attributed to the heterogeneity of cell types that differ in their capacities for growth, differentiation, and metastases.
We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its
ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic
pheochromocytoma (PHEO). Subsequently, we evaluated the increased efficacy of chemotherapy combined with LB1.
Methodology/Principal Findings: The effect of LB1 and temozolomide (TMZ), a standard chemotherapeutic agent that
alone only transiently suppressed the growth and regression of metastatic PHEO, was evaluated in vitro on a single PHEO
cell line and in vivo on mouse model of metastatic PHEO. In the present study, we show that metastatic PHEO, for which
there is currently no cure, can be eliminated by combining LB1, thereby inhibiting PP2A, with TMZ. This new treatment
approach resulted in long term, disease-free survival of up to 40% of animals bearing multiple intrahepatic metastases, a
disease state that the majority of patients die from. Inhibition of PP2A was associated with prevention of G1/S phase arrest
by p53 and of mitotic arrest mediated by polo-like kinase 1 (Plk-1).
Conclusions/Significance: The elimination of DNA damage-induced defense mechanisms, through transient pharmacologic
inhibition of PP2A, is proposed as a new approach for enhancing the efficacy of non-specific cancer chemotherapy regimens
against a broad spectrum of low growth fraction tumors very commonly resistant to cytotoxic drugs.
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Introduction
Cancer therapy has been most successful against aggressive
tumors characterized by a high population of cells in active cell
growth (high-growth fraction), although acquired impairment of
DNA-damage repair mechanisms may underlie the chemotherapy
sensitivity of the most curable cancers [1]. Nevertheless, aggressive
chemotherapy, combined at times with radiation, often cures
several types of rapidly growing poorly differentiated cancers
including leukemias, lymphomas, testicular cancers, and gesta-
tional choriocarcinomas, even though they are disseminated at
diagnosis. This is not the case for the most common and more
slowly growing cancers of the prostate, breast, lung, colon, and
ovary, for which a cure is generally not achievable if the tumor
cannot be eliminated completely by surgery/radiation. Whether
these cancers have subsets of intrinsically resistant high-growth
fraction cells or whether they are resistant to cytotoxic therapy
simply because they are not in active cell division is not certain [2].
The distribution of cells in a given cancer at different phases of the
cell cycle may be an important factor in determining the efficacy of
cytotoxic treatment [3,4]. Attempts to overcome cell-cycle
dependent resistance have included administration of drugs to
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e14678preferentially disturb the regulation of the cell-cycle and DNA-
repair in cancers compared to the cells of normal tissues [5,6,7].
Regardless of the mechanisms of resistance, most solid malignant
tumors have a cell population, which survives the most aggressive
combinations of highly cytotoxic drugs given on a variety of
schedules.
In the present study, we wanted to determine whether inhibition
of PP2A also potentiates the effectiveness of temozolomide (TMZ)
against well-differentiated low-growth fraction solid tumors, such
as pheochromocytoma (PHEO). PHEOs arise from chromaffin
cells of the adrenal gland. Comparable tumors arising from
extraadrenal chromaffin cells are termed as paragangliomas
(PGLs). Both tumors are characterized by the synthesis, storage
and release of catecholamines [8]. Most PHEOs and PGLs are
sporadic but about 25% are associated with familial disorders
including multiple endocrine neoplasia type 2, neurofibromatosis
type 1, von Hippel-Lindau syndrome, and syndromes associated
with mutations of genes encoding subunits of the succinate
dehydrogenase complex [9,10,11]. Most of these tumors are not
malignant; however, about 40% of patients presenting with
metastatic disease harbor an underlying mutation, most notably
in the gene for subunit B of the succinate dehydrogenase complex
[12,13]. Because of their high degree of differentiation, malignant
PHEOs and PGLs are diagnosed primarily by demonstrating the
presence of aggregates of chromaffin cells in sites where
chromaffin cells are not normally present and from specific
biochemical abnormalities [14]. Although metastatic PHEOs and
PGLs are generally slow growing, the prognosis of patients with
disseminated disease is poor, with a 5-year survival rate less than
50%. This is due in large part to the fact that, currently, there is no
effective chemotherapeutic regimen [15]. A long-term follow-up
study conducted on 18 patients reported a complete response rate
of 11% and a partial response rate of 44% of metastatic PHEO
and PGL patients after cyclophosphamide, vincristine, and
dacarbazine (CVD) treatment [16]. Moreover, recent studies
demonstrated that the survival rate between patients treated with
CVD chemotherapy and those without treatment did not differ
[16,17].
TMZ has been reported to have some therapeutic benefit in the
treatment of metastatic neuroendocrine carcinomas, including
malignant melanomas and PHEOs [18,19,20]. Because of the
marked ability of LB-1.2 to sensitize xenografts of glioblastoma
multiforme and neuroblastoma to TMZ, cancers also minimally
inhibited by TMZ, [21] we studied the anti-tumor activity of LB1
(LB-1, LB-100), a water-soluble homolog of LB1.2 in combination
with TMZ; each compound was also studied individually. All
experiments were conducted against mouse PHEO cells (MPC cell
line) in vitro and against a metastatic model in vivo. At present, the
MPC cell line most closely resembles well-differentiated neoplastic
human chromaffin cells including the expression of tyrosine
hydroxylase and phenylethanolamine-N-methyltransferase [22],
unique markers of catecholamine synthesis.
Results
In vitro and in vivo anti-tumor activity of LB1 and TMZ
and their combination
In vitro, both LB1 and TMZ, at concentrations up to 20 mM and
600 mM, respectively, showed only modestly inhibited MPC cell
proliferation. Even at maximum concentration tested, LB1 drug
did not achieve over 50% inhibition and TMZ only with 600 mM
concentration achieved over 50% inhibition (Figure 1A–1B). Both
Figure 1. In vitro anti- proliferative activity of LB1 and TMZ and their combination. Inhibition of growth of MPC cells in culture: (A and B)
Exposure for 3 days to increasing concentrations of LB1 or TMZ. (C–E) Exposure to increasing concentrations of LB1 plus TMZ. (F) Synergy analysis was
done based on data from (A–E) using CalsuSyn software. CI values: C=1 as additivity; C,1 as synergy; C.1 as antagonism. Combo 1 presents
combination of 5 mM of LB1 and 100, 200, 300 mM of TMZ; Combo 2 presents combination of 7.5 mM of LB1 and 100, 200, 300 mM of TMZ; and
Combo 3 10 mM of LB1 and 100, 200, 300 mM of TMZ.
doi:10.1371/journal.pone.0014678.g001
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of TMZ between 100 and 300 mM and combined with LB1 at
concentrations between 5 and 10 mM (Figure 1C–1E). The
combination index (CI) was used to confirm and quantify the
synergy observed with LB1 and TMZ. CI values were ,0.9 at
almost all doses (range from 5–10 mM of LB1 and 100–300 mMo f
TMZ; Figure 1F), indicating that synergy occurred between LB1
and TMZ. There was no interference of drugs and XTT agent kit
observed at the absence of cells.
We then tested drug efficacy against metastatic PHEO in vivo.
Following intravenous tail vein injection, MPC cells formed
multiple intrahepatic masses, detectable by magnetic resonance
imaging (MRI) starting from the 4
th week post injection.
Untreated, numerous hepatic tumor nodules reach total volumes,
estimated from the MRI images, of 7006100 mm
3 by week 7,
requiring sacrifice of the animals (Figure 2A–2B). Control animals
(untreated animals) received vehicle (phosphate buffered saline-
PBS) alone by continuous infusion (c.i.) for 14 days via an Alzet
capsule implanted intraperitoneally (i.p.) on the 5
th day after tumor
cell injection. LB1 was given by c.i. at 1.5 mg/kg per day for 14
days starting on the 5
th day after tumor cell injection. TMZ was
administered by gavage alone or with LB1 at 80 mg/kg every 3
days on 3 different schedules: 3 doses beginning 10 days from the
start of LB1; 14 doses beginning 10 days from the start of LB1; and
14 doses beginning from the start of LB1.
LB1 alone (n=5) had no inhibitory effect as estimated from
MRI images. In contrary, liver tumors were growing more rapidly
after 14-days of LB1 treatment, even compared to control group
(Figure 2B,C, blue line), demonstrated by weekly MRI and volume
measurements. Three doses of TMZ every 3 days alone slowed
tumor growth slightly in all animals (n=5; Figure 2B and C, green
line), whereas combination of both drugs markedly reduced the
rate of increase in hepatic tumor volume in all animals (n=10
treated animals) compared to tumor volume rate in control
Figure 2. In vivo anti-tumor activity of LB1 and TMZ and histological examination. Effects of treatment upon growth and molecular
changes in hepatic tumors: (A) MRI images of untreated mice at weeks 5, 6, and 7 following intravenous injection of MPC cells and a
photomicrograph showing the growth hepatic lesions and Alzet minipump. Barbed arrow indicates the gall bladder. Plain arrows indicate the same
tumor nodules over time. (B) Inhibition of total hepatic tumor volume by LB1 alone at 1.5 mg/kg daily for 14 days by c.i. administered at 5
th day after
MPC cells injection; TMZ alone at 80 mg/kg for 3 doses administered at 15
th day after MPC cells injection; and, combination of both drugs. (C) Survival
curve combining the data from the study depicted in (B) a total of 10 control animals, 10 animals with combination treatment LB1 and TMZ, 5 animals
with TMZ alone, and 5 animals with LB1 alone. Kaplan-Meier analysis revealed that survival following LB1 plus TMZ was significantly greater than with
LB1 alone and TMZ alone (log rank, P,0.0001). (D) MRI images of mice, treated with the combination of LB1 by c.i. for 14 days and 3 doses of TMZ, at
week 7, 9, and 12. Partial response of treatment is presented with delayed appearance of hepatic tumors compared to untreated group. Complete
response presents absence of hepatic tumors after treatment. A photomicrograph of the liver of one treated animal at week 12, showing the absence
of gross tumor, and the presence of fibrous scar tissue (arrows). (E) Inhibition of estimated total hepatic tumor volume by combination treatment of
LB1 and TMZ. LB1 at 1.5 mg/kg daily for 14 days by c.i. administered at 5
th day after MPC cells injection and TMZ at 80 mg/kg every 3 days for 14
doses beginning on 15
th day after MPC cells injection (with combination or alone). (F) Survival curve combining the data described in E. Total of 12
control animals, 5 animals for TMZ and 7 animals for combination treatment LB1 and TMZ. Survival of animals with combined treatment were
significantly greater compared to controls (log rank, P,0.0001). (G) Serial MRI images of mice, treated with the combination of LB1 and 14 doses TMZ
with partial and complete responses. (H) Histologic features of liver PHEO at week 12 stained with H&E receiving no treatment or LB1 by c.i. and three
doses of TMZ as described in D. Untreated animals showed intrahepatic deposits of cancer cells whereas the liver of an animal receiving both drugs
that had no gross evidence of tumor revealed normal parenchyma and fibrous tissue, believed to be scarring at former sites of tumor masses. (I)
Survival curves of animals treated with LB1 and 14 doses of TMZ when administration started at the same time, on day 5 after MPC cells injection.
(n=5 treated animals with LB1 plus TMZ, n=5 for controls; log rank, P=0.0035).
doi:10.1371/journal.pone.0014678.g002
Treatment for Metastatic PHEO
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e14678animals (n=10; Figure 2B and C, red line). Growth of tumors in
animals given TMZ plus LB1 was delayed to week 9 (Figure 2B),
with 2 of 10 animals having no apparent tumor at 12 weeks by
serial MRIs (Figure 2D). After sacrifice at 12 weeks (Figure 2C),
examination of these two animals showed no hepatic tumor (last
image lower panel Figure 2D).
We then studied the effect of increasing TMZ from 3 to 14
doses every 3 days alone and in combination with LB1; TMZ
dosing started 10 days after LB1. The study was done in two
stages: TMZ alone (n=5) versus vehicle alone (n=5) and TMZ
plus LB1 (n=7) versus vehicle alone (n=7). Fourteen doses of
TMZ alone delayed development and growth of the tumors from 5
to 8 weeks in all animals but tumor progression required sacrifice
by week 10. LB1 plus TMZ delayed tumor growth in all animals to
12 weeks (log rank: P,0.0001, Figure. 2E–2F). Two of these mice
required sacrifice at week 14 and 15 and 3 animals, without
apparent disease as shown by MRI, (Figure 2G) were sacrificed at
16 weeks and were found to be free of hepatic tumors. Histological
sections showed multiple healthy viable appearing clusters of
tumor cells in livers of untreated animals but only scar tissue in
damaged liver parenchyma without viable tumor cells seen in the
animals having complete tumor regressions (Figure 2H).
In a third study, the effect of 14 doses of TMZ every 3 days,
beginning the same day as initiation of LB1, rather than day 10 of
LB1 (n=5), was compared to a concomitant control group (n=5).
Tumor growth was suppressed or delayed in all treated animals; 2
animals required sacrificing at week 15 and 16. Three animals
sacrificed at week 17 had no evidence of hepatic tumors (Figure 2I).
There was no apparent drug toxicity based on observation of the
mice and documented absence of significant weight loss on any
treatment arm.
Molecular and cell cycle analyses of MPC tumor cells
treated with LB1, TMZ and their combination
We compared the extent of phosphorylation of pAkt (ser 308),
polo-like kinase 1 (Plk-1), pPlk-1(thr 210), and pMDM2 (ser 166) to
the relative amounts of p53 (ser 15) treated MPC cells compared to
controls, and in treated compared to untreated hepatic tumors. MPC
cells cultured for 24 hours and exposed to vehicle, LB1 (5 mM), TMZ
(50 mM), and their combination, revealed changes in pAkt, pPlk-1,
and pMDM2 and p53 expression (Figure 3A–3C). LB1 and
combination of LB1 and TMZ exposure increases pAKT on MPC
cells. TMZ does not noticeably change the expression of pAKT.
LB1 had no effect on expression of p53 but exposure to TMZ
markedly increased expression of p53, however, LB1 alone or in
combination with TMZ increased the expression of pMDM2 in
MPC cells. The combination of LB1 and TMZ increased
expression of pPlk-1.
The tumors were examined 24 hours after single administration
of LB1 (1.5 mg/kg, i.p.), TMZ (80 mg/kg, by gavage) or
combination of both drugs at the same concentrations. Comparing
to GBM xenografts [21], exposure of metastatic PHEOs to LB1
alone increased pAkt, pPlk-1, and pMDM2 and had little effect on
p53. Exposure to TMZ alone reduced pPlk-1 and markedly
increased p53 without a change in pMDM2. The combination of
LB1 and TMZ, however, prevented the TMZ-induced decrease in
pPlk-1, increased the concentration of pMDM2 and eliminated
p53 induction (Figure 4A–4C).
We analyzed the cell cycle status of MPC cells growing
exponentially in culture after exposure for 48 hours to vehicle,
LB1 (5 mM), TMZ (50 mM), and combination of both drugs at the
same concentrations. The majority of control cells were in G0/
G1phase (86%) with less than 5% in S phase and about 8% in G2/
M phase. Exposure to LB1 or to TMZ only modestly changed
these distributions, with TMZ causing a slight increase in G0/G1
and S phase cells and a slight reduction in G2/M phase cells. The
combination of drugs altered the cell cycle with a 15% decrease in
G0/G1 and a 100% increase in cells in S and G2/M phases,
compared to control cells (Figure 5A) indicates loss of checkpoints
in G1 and G2 ordinarily induced by acute DNA-damage.
Apparently, cell death proceeded by induction of mitotic
catastrophe rather than by apoptosis in cells exposed to both
drugs, as indicated by the absence of low molecular weight (50kD)
PARP, in cells treated with both drugs as compared to TMZ alone
(Figure 5B). In vivo, combination treatment resulted in extensive
necrosis of tumor cells (Figure 6).
Discussion
In the present study, all animals with metastatic PHEOs, treated
with combination of drugs LB1 plus TMZ, had a significant delay
in liver tumor growth and 40% of treated animals were found to
be tumor free. There was no toxicity in mice receiving LB1 and
TMZ in combination. Inhibition of PP2A was associated with
prevention of G1/S phase arrest by p53 and mitotic arrest
mediated by Plk-1. Simultaneous elimination of DNA damage-
induced defense mechanisms, through transient pharmacologic
inhibition of PP2A, is proposed as a new method for enhancing the
efficacy of non-specific cancer chemotherapy regimens against a
broad spectrum of low growth fraction tumors, such as PHEOs,
that are commonly resistant to cytotoxic drugs.
The alterations induced by inhibition of PP2A that appeared to
be responsible for changes in cell cycle parameters are mediated
by increased phosphorylation of Akt-1, which in turn increases
phosphorylation of pMDM2 [23,24], and pPlk-1. Phosphorylation
of MDM2 leads to degradation of p53, which, in the presence of
Figure 3. Western blot on MPC cells. Changes in pAKT, p53, pMDM2, and pPlk-1 after 24 hours treatment on MPC cells with 5 mM of LB1, 50 mM
of TMZ and combination of both drugs. (A) Western blots show that LB1 exposure increases pAKT compared to control MPC cells (untreated, only
vehicle). TMZ does not noticeably change the expression of pAKT and combination of LB1 and TMZ highly increases pAKT expression. (B) A
demonstration of markedly increased expression of p53 after TMZ treatment but inhibition of expression by exposure to LB1. Noticeable increase in
the expression of pMDM2 in MPC cells treated with LB1 alone or in combination with TMZ. (C) Noticeable increases in expression of pPlk1 in MPC cells
after exposure to the combination of drugs.
doi:10.1371/journal.pone.0014678.g003
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cycle arrest. Mitotic arrest can be caused not only by direct
inhibition of microtubules during mitosis (e.g., paclitaxel-induced
mitotic arrest) but also by DNA damage prior to mitosis (in the
interphase of the cell cycle) [25]. Perhaps equally important is the
activation, more specifically phosphorylation, of Plk-1 in the
presence of DNA damage through inhibition of Plk1. Smits and
colleagues showed that over-expression of activated Plk-1 can
block mitotic arrest induced by DNA-damage [26]. Recently, Jang
and coworkers demonstrated that a reduction in phosphorylated
Plk in response to DNA damage during mitosis is mediated by
PP2A and that okadaic acid, a natural product inhibitor of PP2A,
inhibits the reduction of phosphorylated Plk1 induced by DNA
damage [27]. We suggest that potentiating the anti-cancer activity
of TMZ by inhibition of PP2A is caused by abrogation of the
mitotic checkpoint by enhanced phosphorylation of Plk-1 and the
simultaneous inhibition of cell cycle arrest in G1/S that results
from the marked reduction in p53 driven by increased pMDM2.
The net result is continued entry of cancer cells from G0/G1 into
S phase and S phase into G2/M phases despite the presence of
acute DNA damage that would ordinarily arrest the cell cycle in
the G1 and G2 phases. It appears that this is a dynamic process by
which cancer cells are prevented from completing replication over
several days in the animal, perhaps accounting for the very modest
effects of the drug combination in short term culture in vitro.
Interestingly, liver tumors were growing more after 14-days of LB1
Figure 4. Western blot on PHEO tumors. Changes in the state of phosphorylation and abundance of small pAKT, p53, pMDM2, and pPlk-1
24 hours after treatment of mice bearing hepatic tumors with vehicle, LB1 alone at 1.5 mg/kg by gavage, TMZ alone by gavage at 80 mg/kg, of both
drugs at the same doses. (A) Western blots show that LB1 exposure increases pAKT in control-untreated tumors and treated tumors. TMZ does not
change the expression of pAKT and combination of LB1 plus TMZ highly increases pAKT expression. (B) Western blots demonstrate marked increased
expression of p53 after TMZ but complete inhibition of this induction by exposure to LB1 accompanied by an increase in the expression of pMDM2 in
tumor cells exposed to LB1 alone or in combination with TMZ (C) Expression of pPlk1 shows a marked increase in tumors after exposure to the
combination of drugs.
doi:10.1371/journal.pone.0014678.g004
Figure 5. Effect of LB1 and TMZ on tumor cell cycle and apoptosis. (A) Cell cycle analysis of MPC cells in exponential growth exposed for
48 hours to vehicle alone; LB1 alone at 5 mM; TMZ at 50 mM and; LB1 at 5 mM and TMZ at 50 mM. (B) PARP expression changes in 24 hours after
treatment of mice bearing hepatic tumors with vehicle, LB1 alone at 1.5 mg/kg by gavage, TMZ alone by gavage at 80 mg/kg, of both drugs at the
same doses.
doi:10.1371/journal.pone.0014678.g005
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animals were dying faster. This observation was in correlation with
cell cycle data, where tumor cells were pushed more into the S and
G2/M phase. Thus, LB1 sensitized more tumor cells to the same
cell cycle stage where targeted treatment with TMZ would be
more effective. TMZ alone did not prevent from tumors’
development, however, combined with LB1 was survival of
animals significant. These results also confirm cell cycle data,
where drug combination altered the cell cycle with a 15% decrease
in G0/G1 phase, and 100% increase in S and G2/M phase.
We presume that the cancer cell genome has several, if not
multiple acquired defects in genes for proteins controlling cell
cycle, rendering cancer cells less tolerant than normal cells to
modulation of phosphorylation mediated through signal transduc-
tion [21,28]. Goodzari et al. presented that global perturbations in
regulatory elements of human cancer, showed a general over-
expression of mitotic pathways, including 11 associated with DNA
repair in cancer cells compared to normal cells [29].
Toxicity permitting, the combination of a small molecule
inhibitor of PP2A and an agent targeting DNA, such as
chemotherapy and x-radiation, may provide newer and more
effective treatments for a broad spectrum of human cancers
despite large differences in their degrees of differentiation and
growth rates. The proposed cancer therapy approach in the
present study is novel and has far reaching implications as a major
advancement in the treatment of metastatic cancer such as
metastatic PHEO and PGL. Our results indicate that LB1 helps to
potentiate the cytotoxicity effect of chemotherapy against
metastatic PHEO in a mouse model. This finding can be extended
to the clinic in the treatment of resistant PHEO and PGL as there
is currently no successful treatment of this disease.
Methods
Materials and culture
Mouse PHEO (MPC 4/30PRR) cells were a gift from A.S.
Tischler [22]. MPC cells were maintained in Dulbecco’s Modified
Minimum Essential Medium (DMEM, Gibco, USA, heat-
inactivated horse serum (Hyclone Logan, UT), fetal bovine serum
(GIBCO, Grand Island, NY), penicillin (10,000 units/ml)/
streptomycin (10,000 units/ml) (GIBCO, Grand Island, NY),
and maintained at 37uC with 5% CO2. MPC cells were grown in
tissue culture dishes without collagen. We have verified that MPC
cells are uninfected with mycoplasma. Prior to injection into mice,
MPC were incubated in 0.05% trypsin (GIBCO), and gently
rocked at 37uC until they detached from the flask. Cells were
transferred to a 15 ml conical tube containing fresh medium and
then washed and re-suspended in 100 ml of medium before
injection into nude mice. TMZ was purchased from Sigma-
Aldrich Co., St. Louis, MO. LB1 (also designated LB-100 [30])
was provided by Lixte Biotechnology Holdings, Inc. (LBHI).
Cytotoxicity assay
The antiproliferative activity of LB1 and TMZ on cells at
varying concentrations was examined by the XTT assay (Cell
Proliferation Kit II, Roche Diagnostics Corporation, Roche
Applied Science, Indianapolis, IN). After dissociation, MPC
cells (passage 25–28, in vivo and in vitro)w e r es e e d e di n9 6 - w e l l
plates coated with collagen (15,000 cells/well) and incubated at
37uC. LB1 in concentrations of 2, 5, 10, 15 and 20 mMa n d
TMZ in concentrations of 100, 200, 300, 400, 500 and 600 mM
and in various combinations were added 24 hours after cell
seeding and incubated at 37uC. To test a potential interference
of XTT kit reagents and drugs, LB1 and TMZ were tested in
absence of cells and evaluated with XTT reagent kit.
Antiproliferative activity was measured 24, 48 and 72 hours
after drug administration. The XTT labeling mixture was
added, and the plates were incubated for an additional 6–
24 hours, after which spectrophotometric absorbance was
measured with a microplate reader (Bio-Rad Laboratories,
Philadelphia, PA) according to the manufacturer’s instructions.
All experiments were performedi nt r i p l i c a t ea n dr e p e a t e da t
least twice. The concentration of drugs that reduced cell survival
by 50% (IC50) as compared to controls was calculated. The
survival of treated cells was expressed as a percentage of control
(vehicle treated) cultures.
Synergy analysis of combined drug effects
Drug synergy was determined from median effect analysis by
Chou-Talalay equations [31] using the CalcuSyn software
(Biosoft). Using cell proliferation assay and computerized data,
Combination index (CI) was generated between LB1 and TMZ
drugs. Additivity was then defined as CI=1; synergy as CI,1; and
antagonism as CI.1.
Figure 6. Histolopathology. Histologic features of liver PHEO lesions stained with H&E 24 hours after i.p. vehicle alone (left) or with i.p. LB1 at
1.5 mg/kg plus TMZ by gavage at 80 mg/kg (right). Exposure to a single i.p. injection of vehicle showed a homogeneous field of healthy appearing
tumor cells, whereas combination treatment resulted in extensive necrosis of tumor cells.
doi:10.1371/journal.pone.0014678.g006
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All animal studies were conducted in accordance with the
principles and procedures outlined in the National Institute of
Health Guide for the Care and Use of Animals, and approved by
the Eunice Kennedy Shriver National Institute of Child Health
and Human Development Animal Care and Use Committee.
Female athymic nude mice (NCr-nu) were obtained from Taconic
Inc. (Germantown, MD) and were housed in a pathogen-free
facility. The mice were acclimated for at least 3 days in the animal
facility in which the appropriate temperature, humidity and light
cycle (6:00 A.M. – 6:00 P.M) were controlled, with ad libitum access
to food and water. Each experimental group consisted of six to ten-
week old mice. Non-anaesthetized mice were intravenously
injected in the tail vein using a 1 ml syringe and 30 1/2 gauge
needles with 1610
6 MPC cells (passage 25–28) in 100 mlo f
medium. Mice were monitored daily and examined by weekly
MRI for the number and extent of tumor growth in the liver.
Drug administration
LB1 and vehicle were given via a mini-osmotic pump (model
1002 Alzet, Cupertino) that was implanted intraperitoneally while
the animals were under anesthesia. The pump was filled under
sterile conditions, per the manufacturer’s instructions, with either
100 ml of LB1 (0.03 mg/day dissolved in PBS) or PBS as vehicle
into control mice. The pumps had a mean flow rate of 0.25 ml/
hour for the 2-week study duration. TMZ (80 mg/kg) was given
by gavage every 3 days at either 3 or 14 doses. Animals were
weighed once a week and monitored daily for possible side effects
of the drugs. Those with significant tumor burden were sacrificed.
It is important to note that the metastatic PHEO model presents
practical challenges since the stress imposed by manipulation
cause the release of catecholamines from tumors and frequent
animal demise [32]. Therefore, we have decided to use the mini-
osmotic pump for LB1 administration in order to minimize animal
handling. This approach was also based on our previous
experience using osmotic pumps [33], when excellent results were
obtained delivering drugs systematically. In the same manner,
frequent i.p. injections would be difficult to perform due to possible
tumor perforation and hemorrhage (liver tumors filled the entire
peritoneal cavity).
Magnetic resonance imaging
Tumor growth in the liver was monitored by MRI once a week
starting at the 3
rd week after the MPC cells i.v injection. Usually,
tumors started to be visible in week 4 and fully measurable in week
5. For MRI studies, mice were anesthetized with inhaled
isoflurane/O2 at a dose of 1.5–5% v/v adjusted to produce a
respiratory rate of approximately 40 breaths per minute. Mice
were placed in the prone position and kept warm during the
scanning as well as during post-scan recovery from anesthesia. Fat-
suppressed, T2-weighted spin echo images were acquired on a
clinical Philips Intera 3.0 Telsa (3T) system, using a dedicated
40 mm inner diameter solenoid coil (Philips, Best, Netherlands). A
total of 40 slices were acquired with TE/TR 65/4500 ms; slice
thickness was 0.5 mm, 0.1660.16 mm
2 in-plane resolutions with a
scan time of 5–7 minutes for two signal averages. MRI data was
acquired and reconstructed using the scanner software (Intera,
Philips Medical System, Best, Netherlands). Quantitative mea-
surements of volume changes were obtained using the ImageJ and
MIPAV software [34]. The size and volume measurements of liver
tumors were performed as described before [35] Measurements
were taken from groups containing five animals.
Histological, biochemical and molecular characterization
Animals were euthanized using CO2 inhalation and cervical
dislocation. Tumors were resected from the excised liver and then
formalin-fixed, paraffin-embedded and sectioned (10 mm). Hema-
toxylin and eosin (H&E) staining was performed.
Western blot studies
Primary antibodies to p-Akt (Thr308), p53 (ser-15), PARP and
MDM2 (ser-166) were purchased from Cell Signaling Technology
Inc. (Danvers, MA). Plk1 (T210) was purchased from Abcam Inc.
(Cambridge, MA). To determine the effects of LB1 on Akt, Plk1,
p53, and MDM2, cultured MPC cells were treated with vehicle
control, 5 mM LB1, 50 mM of TMZ and their combination. After
24 hours of treatment, cultured cells were harvested and resus-
pended in T-PER solution, sonicated, and centrifuged. Animals
bearing hepatic tumors were treated with vehicle, LB1 alone, TMZ
alone and the combination of LB1 and TMZ. After 24 hours,
animalsweresacrificed and tumortissue wassectioned,resuspended
in T-PER solution, sonicated and centrifuged. The protein
concentration in each sample was measured by a colorimetric
assay (Bio-Rad Protein Assay Kit) (Bio-Rad; Hercules, CA).
Expression of specific proteins in each sample was determined via
Western blotting using primary antibodies. Detection of protein-
bound primary antibodies was performed with a horseradish
peroxidase-conjugated secondary antibody specific to rabbit
immunoglobulin and an enhanced chemiluminescence system.
Cell cycle analyses
MPC cultured cells were treated with vehicle or the test regimen
for 48 hours. Following culture, cells were fixed with 70 ethanol
overnight at 220uC. The fixed cells were stained with 10 mg/ml
PI and 1 mg/ml RNase for 30 minutes and analyzed by FACS
[36].
Statistical analysis
Results from the XTT cell viability assay and volume
measurements of liver lesions are presented as mean6standard
error of the mean (SEM). Statistical differences between groups
were assessed by ANOVA, followed by Student-Neuman-Keuls
test for group comparison. The level of statistical significance was
set at P,0.05. Differences in animal survival rates were
determined by Kaplan-Meier Analysis. A probability value of
P,0.05 was considered significant.
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